全文获取类型
收费全文 | 46201篇 |
免费 | 3970篇 |
国内免费 | 110篇 |
专业分类
耳鼻咽喉 | 378篇 |
儿科学 | 1894篇 |
妇产科学 | 1293篇 |
基础医学 | 6574篇 |
口腔科学 | 967篇 |
临床医学 | 6429篇 |
内科学 | 8982篇 |
皮肤病学 | 903篇 |
神经病学 | 4760篇 |
特种医学 | 1077篇 |
外科学 | 4101篇 |
综合类 | 404篇 |
一般理论 | 62篇 |
预防医学 | 5588篇 |
眼科学 | 665篇 |
药学 | 2644篇 |
2篇 | |
中国医学 | 53篇 |
肿瘤学 | 3505篇 |
出版年
2023年 | 397篇 |
2022年 | 260篇 |
2021年 | 1137篇 |
2020年 | 944篇 |
2019年 | 1407篇 |
2018年 | 1539篇 |
2017年 | 1206篇 |
2016年 | 1338篇 |
2015年 | 1405篇 |
2014年 | 1786篇 |
2013年 | 2630篇 |
2012年 | 3669篇 |
2011年 | 3781篇 |
2010年 | 2075篇 |
2009年 | 1839篇 |
2008年 | 3056篇 |
2007年 | 3141篇 |
2006年 | 3089篇 |
2005年 | 2906篇 |
2004年 | 2816篇 |
2003年 | 2572篇 |
2002年 | 2316篇 |
2001年 | 356篇 |
2000年 | 245篇 |
1999年 | 289篇 |
1998年 | 416篇 |
1997年 | 304篇 |
1996年 | 269篇 |
1995年 | 330篇 |
1994年 | 263篇 |
1993年 | 255篇 |
1992年 | 184篇 |
1991年 | 164篇 |
1990年 | 155篇 |
1989年 | 111篇 |
1988年 | 134篇 |
1987年 | 89篇 |
1986年 | 98篇 |
1985年 | 98篇 |
1984年 | 104篇 |
1983年 | 100篇 |
1982年 | 127篇 |
1981年 | 121篇 |
1980年 | 100篇 |
1979年 | 63篇 |
1978年 | 68篇 |
1977年 | 50篇 |
1976年 | 47篇 |
1974年 | 42篇 |
1973年 | 40篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Cornelius Anna Pilger Daniel Riechardt Aline Reitemeyer Emanuel Rübsam Anne Winterhalter Sibylle Maier Anna-Karina B. 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(3):957-965
Graefe's Archive for Clinical and Experimental Ophthalmology - To compare the blood flow situation in primary open-angle glaucoma (POAG) and pseudoexfoliation glaucoma (PXG) using optical... 相似文献
2.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
3.
4.
5.
6.
7.
8.
9.
Sine Wichmann Martin Schønemann-Lund Anders Perner Theis S. Itenov Theis Lange Christian Gluud Rasmus E. Berthelsen Anne C. Brøchner Jørgen Wiis Morten H. Bestle 《Acta anaesthesiologica Scandinavica》2023,67(4):470-478
Background
Salt and water accumulation leading to fluid overload is associated with increased mortality in intensive care unit (ICU) patients, but diuretics' effects on patient outcomes are uncertain. In this first version of the GODIF trial, we aimed to assess the effects of goal-directed fluid removal with furosemide versus placebo in adult ICU patients with fluid overload.Methods
We conducted a multicentre, randomised, stratified, parallel-group, blinded, placebo-controlled trial in clinically stable, adult ICU patients with at least 5% fluid overload. Participants were randomised to furosemide versus placebo infusion aiming at achieving neutral cumulative fluid balance as soon as possible. The primary outcome was the number of days alive and out of the hospital at 90 days.Results
The trial was terminated after the enrolment of 41 of 1000 participants because clinicians had difficulties using cumulative fluid balance as the only estimate of fluid status (32% of participants had their initially registered cumulative fluid balance adjusted and 29% experienced one or more protocol violations). The baseline cumulative fluid balance was 6956 ml in the furosemide group and 6036 ml in the placebo group; on day three, the cumulative fluid balances were 1927 ml and 5139 ml. The median number of days alive and out of hospital at day 90 was 50 days in the furosemide group versus 45 days in the placebo group (mean difference 1 day, 95% CI -19 to 21, p-value .94).Conclusions
The use of cumulative fluid balance as the only estimate of fluid status appeared too difficult to use in clinical practice. We were unable to provide precise estimates for any outcomes as only 4.1% of the planned sample size was randomised. 相似文献10.
Die Anaesthesiologie - 相似文献